eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2020
vol. 16
 
Share:
Share:
more
 
 
abstract:
Original paper

Impact of percutaneous patent foramen ovale closure on migraine headaches in patients with history of ischemic neurological events

Przemysław Węglarz
1
,
Katarzyna Spisak-Borowska
2
,
Tomasz Bochenek
3
,
Ewa Konarska-Kuszewska
3
,
Jerzy Machowski
2
,
Maria Trusz-Gluza
3
,
Grzegorz Bajor
1
,
Katarzyna Mizia-Stec
3
,
Joel P. Giblett
4
,
Patrick A. Calvert
4

1.
Department of Human Anatomy, Medical University of Silesia, Katowice, Poland
2.
Neurology Department, Oswiecim Hospital, Oswiecim, Poland
3.
Department of Cardiology, Medical University of Silesia, Katowice, Poland
4.
Department of Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom
Adv Interv Cardiol 2020; 16, 3 (61): 315–320
Online publish date: 2020/10/02
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Observational studies have shown that migraine has been associated with patent foramen ovale (PFO). Whilst studies investigating PFO closure for the treatment of migraine have been neutral, there is some evidence that symptoms of migraine may improve if the PFO was closed after ischemic stroke.

Aim
To establish whether closure of PFO in patients with stroke or transient ischemic attack (TIA) is associated with reduction in the severity of co-existent migraine headaches.

Material and methods
Patients with ischemic stroke or TIA, PFO suitable for percutaneous closure and migraine, were given migraine severity questionnaires prior to PFO closure. These were followed up at 6 and 12 months after closure with the same questionnaire. The primary endpoint was change in migraine severity using the Migraine Severity Scale (MIGSEV). Migraine episode frequency, disability (using the MIDAS scale), and pain intensity were also assessed.

Results
Sixty-two patients were included in the analysis. MIGSEV scores reduced from 7 (7–8) at baseline to 4 (3.25–6) at 6-month follow-up, and 3 (0–4) at 12-month follow-up (p < 0.001). Other measures of migraine headache were also improved at both 6- and 12-month follow-up. Twenty-four (38%) patients were rendered migraine free at 12 months.

Conclusions
PFO closure for stroke or TIA prevention in patients with migraine was associated with a reduction in markers of migraine headache severity.

keywords:

migraine, headache, patent foramen ovale, stroke, patent foramen ovale closure

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe